IBRX vs. TGTX, IOVA, SANA, HRMY, NBIX, TECH, QGEN, RGEN, PCVX, and EXEL
Should you be buying ImmunityBio stock or one of its competitors? The main competitors of ImmunityBio include TG Therapeutics (TGTX), Iovance Biotherapeutics (IOVA), Sana Biotechnology (SANA), Harmony Biosciences (HRMY), Neurocrine Biosciences (NBIX), Bio-Techne (TECH), Qiagen (QGEN), Repligen (RGEN), Vaxcyte (PCVX), and Exelixis (EXEL). These companies are all part of the "medical" sector.
TG Therapeutics (NASDAQ:TGTX) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking.
TG Therapeutics has a beta of 2.3, indicating that its stock price is 130% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.
TG Therapeutics has a net margin of 14.24% compared to TG Therapeutics' net margin of -198,994.05%. ImmunityBio's return on equity of 31.34% beat TG Therapeutics' return on equity.
TG Therapeutics received 648 more outperform votes than ImmunityBio when rated by MarketBeat users. Likewise, 76.77% of users gave TG Therapeutics an outperform vote while only 13.04% of users gave ImmunityBio an outperform vote.
58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 9.2% of TG Therapeutics shares are owned by company insiders. Comparatively, 83.4% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
TG Therapeutics presently has a consensus target price of $29.83, indicating a potential upside of 88.22%. ImmunityBio has a consensus target price of $6.00, indicating a potential downside of 1.64%. Given ImmunityBio's stronger consensus rating and higher probable upside, research analysts plainly believe TG Therapeutics is more favorable than ImmunityBio.
TG Therapeutics has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, TG Therapeutics had 1 more articles in the media than ImmunityBio. MarketBeat recorded 7 mentions for TG Therapeutics and 6 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.02 beat TG Therapeutics' score of 0.33 indicating that TG Therapeutics is being referred to more favorably in the media.
Summary
TG Therapeutics beats ImmunityBio on 16 of the 18 factors compared between the two stocks.
Get ImmunityBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmunityBio Competitors List
Related Companies and Tools
